Market Overview

The Medicines Co., Bristol-Myers Begin Alliance for Recothrom

Related MDCO
The Medicines Company Appoints Sarissa Capital Management Exec To Its Board Of Directors
7 Biotech Traders Pick Their Favorite Stocks For 2016
Related BMY
Is Big Pharma Hinting At A SMID-Cap Biotech Rally?
Earnings Recap For January 28
Upcoming Events - Bayer's Lung Cancer Effort And Apricus And Zealand Try Again (Seeking Alpha)

The Medicines Company (NASDAQ: MDCO) announced today that the global license and two-year collaboration for Recothrom(R), a recombinant thrombin approved by the U.S. Food and Drug Administration for use as a topical hemostat to control non-arterial bleeding during surgical procedures, established with Bristol-Myers Squibb Company (NYSE: BMY) has become effective. The agreement was first announced in December 2012. The companies have satisfied all required regulatory and closing conditions.

Posted-In: News


Related Articles (MDCO + BMY)

View Comments and Join the Discussion!

Get Benzinga's Newsletters